Tag Archive: AIDS

  1. EAVI2020 continues the fight | World AIDS Day 2021

    Leave a Comment

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

    Click on each image to find out about EAVI2020’s clinical trials.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

  2. World AIDS DAY Part 1: EAVI2020’s research to a better future | Trial EAVI2020_3Sm

    Leave a Comment

    Hi! I’m the EAVI2020-3Sm trial and I am testing the VAC02 vaccine. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly Neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. The first in man clinical trial will discern the safety and the immunogenicity of VAC02 as well as the induction of broadly neutralizing antibodies against HIV-1.

    Let me introduce you the team: Robin Shattock (Imperial College London, Study sponsor, UK), Behazine Combadiere, Vincent Vieillard and Patrice Debre (Institut National de Santé et de Recherche Medicale – Inserm, Cimi-Paris, France), Agence Nationale de Recherche sur le SIDA et Maladies Infectieuses Emergentes (ANRS-MIE, France) and Minka Therapeutics (France), they all work together to ensure I am successful!

    Progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Peptide-based vaccination has become one of the challenges of this decade. Based on the discovery of natural broadly neutralizing antibodies against a conserved short epitope of GP41 in long-term non progressor HIV+ patients however rarely observed in HIV progressors, the EAVI2020-3Sm trial will be pioneering in the induction of such antibodies against HIV in man using VAC02 designed vaccine. Furthermore, the translation of VAC02 vaccine candidate into an experimental medicine (EM) study with results expected in 2022 will accelerate progress in the development of an HIV-1 vaccine.

    Find out more about the other EAVI2020 trials taking place:

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2022, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  3. World AIDS DAY Part 4: EAVI2020’s research to a better future | Trial HIV-CORE 0051

    Leave a Comment

    Hi! I am Trial HIV-CORE 0051. I am a phase 1/2a open-label trial to assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.HTI and MVA.HTI given sequentially to healthy HIV-1/2 negative adult volunteers at the Jenner Institute, University of Oxford. Our trial aims to establish the initial safety and immunogenicity of the candidate on the path towards a preventive use of this strategy and is complemented by a series of HIV cure trials in early-treated PLWH.

    The HIV-CORE 0051 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non-Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze along with the many other team members that make up the HIV-CORE 0051 Trial team, in close collaboration with AELIX.

    The trial evaluates a candidate T-cell vaccine, which are being developed by a biotech company, AELIX Therapeutics. The regimen utilizes a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with a replication-deficient poxvirus vector called MVA. Both vectors deliver protein HTI (HIVACAT T-cell Immunogen) designed to generate protective HIV-1-specific T-cell targeting vulnerable sites of HIV-1. The HTI design was informed by human data, whereby the HTI-specific T cells were associated with better viral control in more than 1,000 people living with HIV-1 (PLWH) within a broad HLA class I and class II allele coverage. The immunogen was designed by the team led by Professor Christian Brander and Dr Beatriz Mothe at the Institut de Recerca de la Sida – IrsiCaixa in Barcelona.

    For the last decade, the HIV vaccine development has been almost entirely preoccupied with antibody-based protection, while the T-cell vaccines have been sadly ignored. It is only recently that highly rational T-cell strategies are being resurrected mainly in the context of HIV cure, where effective killer T cells will likely be key for drug-free HIV remission, perhaps even eradication. Current prevention focuses on behavioural and biomedical interventions and provision of antiretroviral drugs, however, an effective HIV-1 vaccine will help many people beyond the reach of today’s treatment and prevention options. Our trial which is aiming to understand the mechanisms and paths towards induction of protective T cells is therefore highly topical.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  4. World AIDS DAY Part 5: EAVI2020’s research to a better future | Trial BCN03

    Leave a Comment

    Hi, I am EAVI2020 trial BCN03. Our trial takes place at IRSICAIXA with Christian Brander (Principal Investigator, IRSICAIXA) Beatriz Mothe (Principal Investigator, IRSICAIXA), working in collaboration with Rogier Sanders (Principal Investigator, AMC) and Dietmar Katinger (Principal Investigator, POLYMUN). Our trial focuses on a combined T- and B-cell, therapeutic HIV vaccine combining the HTI T cell vaccines with SOSIP envelope immunogens.

    Our trial is primarily focusing on the safety of the intervention and whether the intervention can induce sustained virus control once antiretroviral therapy (ART) is stopped. What sets our trial apart is that this is the first therapeutic vaccine trial that combines potent T and B cell immunogens in a combination regimen. We are hoping that this trial will test whether the addition of a B cell immunogen component to a T cell vaccine regimen can improve post-vaccination virus control compared to a single component regimen.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  5. World AIDS DAY Part 2: EAVI2020’s research to a better future | Trial HIV-CORE 0052

    Leave a Comment

    Hi! I am Trial HIV-CORE 0052; a phase I open-label trial aiming to establish and assess the safety and immunogenicity of candidate T-cell vaccines ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3+MVA.tHIVconsv4 given in combination to healthy volunteers at low risk for HIV-1 infection at The Jenner Institute, University of Oxford London (Trial Sponsor) which will be followed by further studies towards both prevention of HIV infection and an HIV cure.

    The HIV-CORE 0052 team including Dr Paola Cicconi (Principal Investigator) Prof Tomáš Hanke (Non Clinical Principal Investigator), Dr Nicola Borthwick and Dr Edmund Wee (Immunology Laboratory Leads) and trial managers Dr Alison Crook and Ms Molly Glaze are aiming to test a candidate T-cell vaccine strategy against HIV-1. The tested regimen consists of a prime with engineered replication-deficient simian (chimpanzee) adenovirus vector ChAdOx1 followed by a heterologous boost with two replication-deficient poxviruses called MVA. These vectors deliver three unique mosaic algorithm-computed immunogens derived from the six most functionally conserved regions of the HIV proteome, collectively called HIVconsvX. Two regions are from the Gag including the whole capsid protein p24 and four are from the Pol proteins. These regions are common to most global HIV-1 variants and are hard to change and escape. These vaccines are so-called subunit genetic vaccines, are designated ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVconsv4 and aim to induce protective killer T-cell responses targeting HIV-1 ‘where it hurts’. If effective, they could work across all major HIV-1 clades and be deployed in all geographical regions.

    Throughout the challenging years of HIV vaccine development, when for the last decade most of the field has almost entirely focused on B-cell biology and antibody-based protection, Professor Hanke remained standing as one of a very few T-cell vaccinologists believing in vaccine-inducible protective cellular immunity, improving, and testing his highly rational T-cell strategy, which is now very much at the forefront of the current efforts.

    An HIV vaccine is urgently needed, however, simple vaccine solutions for this most difficult of viruses have remained extremely elusive. Development of an effective vaccine has been a slow and difficult process over four decades, but remarkable progress has been made in recent years. The experience with COVID-19 vaccines underscores how technologies under development for decades, such as RNA vaccines from 2001 and adenoviral vectors since 1991, can suddenly emerge as a leading and highly effective approach by building on decades of effort. Prof Hanke thinks it is likely that T cell-inducing vaccines for HIV-1 will reach this tipping point in the next 5 years and emerge as an additional tool to help control the HIV pandemic.

    Find out more about the other EAVI2020 trials taking place

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial EAVI2020_01

    EAVI2020-01

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  6. World AIDS DAY Part 3: EAVI2020’s research to a better future | Trial EAVI2020_01

    Leave a Comment

    Hi! I am trial EAVI2020_01. Here at Imperial College London, both scientists and clinicians are leading my study which is modelling the interaction between rationally designed synthetic model viral protein immunogens (EAVI2020_01). We are studying immune responses to several different proteins that are modelled on HIV. The immunogens have a protein-adjuvant design and are given as an injection into the arm.

    Despite global efforts, HIV has proven one of the most difficult infections against which to develop a vaccine. We use sophisticated proteins that have been precisely developed to overcome these natural barriers. If the responses are promising, then we will have an early blueprint for making an HIV vaccine. Working on this trial are Professor Robin Shattock (Imperial College London, Scientific Lead), Dr Katrina Pollock (Imperial College London, Chief Investigator), and Dr Hannah Cheeseman (Imperial College London, Laboratory Lead).

    Vaccines are typically developed by focussing on the infection and not the immune response. The effectiveness of these vaccines is dependent on how most of us would usually respond to the infection if we were to come into contact with it. This strategy for making vaccines is restricting. For example, almost everyone who gets exposed to HIV will develop life threatening diseases without treatment.  The usual immune response is not protective.  The EAVI2020_01 study takes a different approach. Proteins that mimic the hidden parts of HIV are given several times to shepherd the body’s response precisely to make antibodies. The aim is that these antibodies will be broadly protective against all strains of HIV.

    The goal of HIV vaccine research is to make vaccines that induce broadly protective antibodies. This study will tell us how close we are to being able to do that. A successful outcome would pioneer the design of new vaccines for HIV and other highly challenging infectious diseases.

    Find out more about the other EAVI2020 trials taking place.

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020 - 3SM

    EAVI2020-3SM

    info card on clinical trial BCN03

    BCN03

    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2021, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  7. In Pictures: EAVI2020 for World AIDS Day 2019

    Leave a Comment

    HIV continues to be a major global public health issue, having claimed more than 32 million lives so far (WHO). In the lead up to World AIDS Day 2019, EAVI2020 researchers reminded us of the necessity for an effective HIV vaccine.

  8. EAVI2020’s third course on HIV immunology and vaccines

    Leave a Comment

    On 23-26 April 2017, EAVI2020 celebrated its Third PhD course on HIV immunology and vaccines.

    The course was organised by project partners Karolinska Institutet and Fundació Clinic per a la Recerca Biomèdica and took place at Karolinska Institutet, Stockholm.

    The topics that were discussed included How to write a grant application,  how to be involved in  Responsible research and innovation activities,  examples of humanitarian action beyond the bench and after PhD, how to transmit the scientific results to the general population and of course scientific issues focuses on  HIV vaccines immunology. The course also included a Workshop on hepatitis, cancer vaccines and adjuvants.

    The students were enthusiastic and motivated active participants, which contributed to making a success of the course!

    More information

    For more information about EAVI2020 and our training courses, please contact us.

  9. Marit van Gils wins the Beijerinck Premium award from the Royal Dutch Academy of Science.

    Leave a Comment

    The Beijerinck Premium is intended to encourage virology research and is awarded every two years.

    Marit van Gils is a post-doc researcher at Academisch Medisch Centrum and is part of the team working in EAVI2020. This award is given to young post-doc researchers in recognition of outstanding virus-related research at a Dutch scientific organisation.
    The ceremony will take place on the 3rd March 2017.

    More information
    For more information please go to the Beijerinck Premium’s website.